New Tuberculosis Vaccine Phase One Clinical Trial Results
A tuberculosis vaccine developed at McMaster University published phase one clinical study results today.
Tuberculosis is a serious public health threat. One-third of world's population is infected with the organism that causes tuberculosis. The current vaccine used to prevent it is ineffective and high incidence of multi-drug resistant tuberculosis is also a problem.
The new vaccine, based on a genetically modified cold virus, was developed in the lab of Zhou Xing, professor of pathology and molecular medicine and the McMaster Immunology Research Centre, who co-led the phase…